Hiroji Iwata
Impact in
- Oncology top 0.02%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Cancer-related Molecular Pathways
- Cancer Research top 0.05%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Papers in
- Oncology 212
- HER2/EGFR in Cancer Research 89
- Cancer Treatment and Pharmacology 47
- Cancer Immunotherapy and Biomarkers 19
- Cancer Research 128
- Breast Cancer Treatment Studies 105
- Co-authors
- Sherene Loi (25 shared papers)Hope S. Rugo (34 shared papers)Seock‐Ah Im (18 shared papers)Carlos H. Barrios (19 shared papers)Peter Schmid (15 shared papers)Luciana Lorena Molinero (11 shared papers)Sylvia Adams (13 shared papers)Eric P. Winer (11 shared papers)
- Journals
- Breast Cancer (70 papers)Annals of Oncology (52 papers)Breast Cancer Research and Treatment (36 papers)Japanese Journal of Clinical Oncology (30 papers)International Journal of Clinical Oncology (15 papers)
- Partner nations
- JapanUnited StatesUnited Kingdom
In The Last Decade
Hiroji Iwata
487 papers receiving 41.3k citations
Hiroji Iwata's Hit Papers
Peers
Comparison fields: 5 of 175
- Oncology 21.1k
- Cancer Research 9.9k
- Pulmonary and Respiratory Medicine 11.4k
- Genetics 1.9k
- Radiology, Nuclear Medicine and Imaging 3.3k
Countries citing papers authored by Hiroji Iwata
This map shows the geographic impact of Hiroji Iwata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroji Iwata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroji Iwata more than expected).
Fields of papers citing papers by Hiroji Iwata
This network shows the impact of papers produced by Hiroji Iwata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroji Iwata. The network helps show where Hiroji Iwata may publish in the future.
Co-authors
The 25 scholars most cited alongside Hiroji Iwata, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 503 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer Hit paper breakdown → | 2005 | 4136 |
| 2 | Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer Hit paper breakdown → | 2018 | 3448 |
| 3 | Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer Hit paper breakdown → | 2019 | 1971 |
| 4 | Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer Hit paper breakdown → | 2019 | 1575 |
| 5 | Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial Hit paper breakdown → | 2016 | 1457 |
| 6 | Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy Hit paper breakdown → | 2017 | 1379 |
| 7 | Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial Hit paper breakdown → | 2020 | 1374 |
| 8 | Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer Hit paper breakdown → | 2015 | 1299 |
| 9 | Association analysis identifies 65 new breast cancer risk loci Hit paper breakdown → | 2017 | 1013 |
| 10 | Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2019 | 966 |
| 11 | Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer Hit paper breakdown → | 2018 | 948 |
| 12 | Large-scale genotyping identifies 41 new loci associated with breast cancer risk Hit paper breakdown → | 2013 | 908 |
| 13 | Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial Hit paper breakdown → | 2020 | 854 |
| 14 | Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer Hit paper breakdown → | 2022 | 791 |
| 15 | Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study Hit paper breakdown → | 2020 | 621 |
| 16 | Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study Hit paper breakdown → | 2018 | 535 |
| 17 | MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer Hit paper breakdown → | 2019 | 510 |
| 18 | Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer Hit paper breakdown → | 2015 | 486 |
| 19 | Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial Hit paper breakdown → | 2022 | 472 |
| 20 | 2013 | 463 |
About Hiroji Iwata
Hiroji Iwata is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Genetics, having authored 503 papers that have together received 42.3k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (105 papers), HER2/EGFR in Cancer Research (89 papers), Advanced Breast Cancer Therapies (73 papers), Cancer Treatment and Pharmacology (47 papers), Breast Lesions and Carcinomas (26 papers), BRCA gene mutations in cancer (25 papers), Cancer Immunotherapy and Biomarkers (19 papers) and Estrogen and related hormone effects (19 papers). The work is most often cited by research in Oncology (21.1k citations), Cancer Research (9.9k citations), Pulmonary and Respiratory Medicine (11.4k citations), Genetics (1.9k citations) and Radiology, Nuclear Medicine and Imaging (3.3k citations). Hiroji Iwata has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Sherene Loi, Hope S. Rugo, Seock‐Ah Im, Carlos H. Barrios, Peter Schmid, Luciana Lorena Molinero, Sylvia Adams, Eric P. Winer, Norikazu Masuda and Jane Yuet Ching Hui. Their work appears in journals such as Breast Cancer, Annals of Oncology, Breast Cancer Research and Treatment, Japanese Journal of Clinical Oncology and International Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.